CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...